Liver Cancer Clinical Trials

1\textsuperscript{st} LINE Therapeutic

**Unresectable**

- **UCI 01-61** A Humanitarian device exemption use protocol of TheraSphere for treatment of Unresectable Hepatocellular Carcinoma (Abi-Jaoudeh)

- **UCI 15-80** Phase III Comparing Pexa-Vec Followed by Sorafenib vs. Sorafenib Pts w/ HCC w/o Prior Systemic Therapy (Abi-Jaoudeh)

- **UCI 15-81** Phase 1 Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Hepatocellular Carcinoma (Abi-Jaoudeh)

- **UCI 16-40** An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects with Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma (Imagawa)

- **UCI 17-97** A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA) (Dayyani)

2\textsuperscript{nd} LINE Therapeutic

**Unresectable or Metastatic**

- **UCI 16-81** Comparing trans-arterial chemoembolization outcome using cone beam CT vs. conventional fluoroscopy (Abi-Jaoudeh)

- **UCI 16-94** Phase IIA Single Arm Study of Treatment of Patients with Advanced Liver Cancer with a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD1 monoclonal antibody (Abi-Jaoudeh)

- **UCI 17-107** A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination with Bevacizumab Compared with Sorafenib in Patients with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (Dayyani)

- **UCI 18-14** A Phase I, Open-Label, Multicenter Dose Escalation Study of RMC-4630 Monotherapy in Adult Patients with Relapsed/Refractory Solid Tumors (Ou)

- **UCI 18-19** An Open-Label, Phase Ib Multicenter Study of IBI308 in Subjects with Advanced/Metastatic Solid Malignancies (Zhu)

**Opening soon**

**Correlative**

- **UCI 03-03** Immunologic Factors Affecting Outcomes in Patients with Liver Cancer (Imagawa)

- **UCI 16-29** Dynamic Contrast Enhanced Magnetic Resonance Imaging as a Biomarker to Predict Response to Liver Tumor Embolization (Lam)

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu